BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

941 related articles for article (PubMed ID: 29890622)

  • 61. Potential clinical utility of liquid biopsies in ovarian cancer.
    Zhu JW; Charkhchi P; Akbari MR
    Mol Cancer; 2022 May; 21(1):114. PubMed ID: 35545786
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Urine-Based Liquid Biopsy for Nonurological Cancers.
    Jain S; Lin SY; Song W; Su YH
    Genet Test Mol Biomarkers; 2019 Apr; 23(4):277-283. PubMed ID: 30986103
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer.
    Rofi E; Vivaldi C; Del Re M; Arrigoni E; Crucitta S; Funel N; Fogli S; Vasile E; Musettini G; Fornaro L; Falcone A; Danesi R
    Pharmacogenomics; 2019 Jan; 20(1):49-68. PubMed ID: 30520336
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine.
    Kerachian MA; Poudineh A; Thiery JP
    Crit Rev Oncol Hematol; 2019 Dec; 144():102827. PubMed ID: 31715326
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Potential of modern circulating cell-free DNA diagnostic tools for detection of specific tumour cells in clinical practice.
    Gašperšič J; Videtič Paska A
    Biochem Med (Zagreb); 2020 Oct; 30(3):030504. PubMed ID: 32774122
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biosensors for liquid biopsy: circulating nucleic acids to diagnose and treat cancer.
    Bellassai N; Spoto G
    Anal Bioanal Chem; 2016 Oct; 408(26):7255-64. PubMed ID: 27497966
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical utility of emerging liquid biomarkers in advanced prostate cancer.
    Vandekerkhove G; Chi KN; Wyatt AW
    Cancer Genet; 2018 Dec; 228-229():151-158. PubMed ID: 28958406
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Extracellular Vesicles: A Brief Overview and Its Role in Precision Medicine.
    Shang M; Ji JS; Song C; Gao BJ; Jin JG; Kuo WP; Kang H
    Methods Mol Biol; 2017; 1660():1-14. PubMed ID: 28828643
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Liquid biopsies: DNA methylation analyses in circulating cell-free DNA.
    Zeng H; He B; Yi C; Peng J
    J Genet Genomics; 2018 Apr; 45(4):185-192. PubMed ID: 29706556
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
    Alix-Panabières C; Pantel K
    Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Multiparametric liquid biopsy analysis in metastatic prostate cancer.
    Hodara E; Morrison G; Cunha A; Zainfeld D; Xu T; Xu Y; Dempsey PW; Pagano PC; Bischoff F; Khurana A; Koo S; Ting M; Cotter PD; Moore MW; Gunn S; Usher J; Rabizadeh S; Danenberg P; Danenberg K; Carpten J; Dorff T; Quinn D; Goldkorn A
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30702443
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation.
    Wang K; Wang X; Pan Q; Zhao B
    Mol Cancer; 2023 Oct; 22(1):167. PubMed ID: 37803304
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs.
    Casagrande GMS; Silva MO; Reis RM; Leal LF
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768828
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Circulating epigenetic biomarkers in lung malignancies: From early diagnosis to therapy.
    Tomasetti M; Amati M; Neuzil J; Santarelli L
    Lung Cancer; 2017 May; 107():65-72. PubMed ID: 27312601
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders.
    Mithraprabhu S; Chen M; Savvidou I; Reale A; Spencer A
    Leukemia; 2021 Oct; 35(10):2771-2783. PubMed ID: 34262132
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer.
    Jia S; Zhang R; Li Z; Li J
    Oncotarget; 2017 Aug; 8(33):55632-55645. PubMed ID: 28903450
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A headlight on liquid biopsies: a challenging tool for breast cancer management.
    Massihnia D; Perez A; Bazan V; Bronte G; Castiglia M; Fanale D; Barraco N; Cangemi A; Di Piazza F; Calò V; Rizzo S; Cicero G; Pantuso G; Russo A
    Tumour Biol; 2016 Apr; 37(4):4263-73. PubMed ID: 26790442
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Role of circulating tumor DNA in the management of patients with colorectal cancer.
    Moati E; Taly V; Didelot A; Perkins G; Blons H; Taieb J; Laurent-Puig P; Zaanan A
    Clin Res Hepatol Gastroenterol; 2018 Oct; 42(5):396-402. PubMed ID: 29627453
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bioplatforms in liquid biopsy: advances in the techniques for isolation, characterization and clinical applications.
    Shah UJ; Alsulimani A; Ahmad F; Mathkor DM; Alsaieedi A; Harakeh S; Nasiruddin M; Haque S
    Biotechnol Genet Eng Rev; 2022 Oct; 38(2):339-383. PubMed ID: 35968863
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cancer diagnosis: from tumor to liquid biopsy and beyond.
    Vaidyanathan R; Soon RH; Zhang P; Jiang K; Lim CT
    Lab Chip; 2018 Dec; 19(1):11-34. PubMed ID: 30480287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.